Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jun 21;220(9):e20221847. doi: 10.1084/jem.20221847

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 Lei et al.

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).

PMC Copyright notice

Figure 5. — The loss of MHC-II in cancer cells diminishes LNM. (A) The mean fluorescence intensity of cell surface MHC-II molecules in 4T1 sgControl and MHC-II knockout cells, with or without IFN-γ (10 ng/ml) treatment for 24 h, measured by flow cytometry. One-way ANOVA was used for statistical analysis, and Tukey’s multiple comparisons test was used for the post-hoc test. (B) The tumor growth of 4T1 sgControl (n = 10) and MHC-II knockout cells (n =10). Student’s t test was used for the statistical analysis. (C) Knockout of MHC-II in cancer cells increases the overall survival of mice. The primary tumors were removed on day 15, and the draining lymph nodes were removed on day 36. (D) Knockout of MHC-II in cancer cells led to a significant decrease in the proportion of cancer cells in the TDLNs. (E) Knockout of MHC-II in cancer cells resulted in a significant reduction in the proportion of Treg cells in the TDLNs. Student’s t test was used for statistical analysis; *, P < 0.05; **, P < 0.01; ****, P < 0.0001.